Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Dry eye device trial aims to unlock secrets in your tears

NCT ID NCT07175909

Symptom relief Sponsor: The Hong Kong Polytechnic University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Sep 17, 2026 · Updated 3 times

Summary

This study tests a device called Rexon-Eye that uses low-level electrical current to treat dry eye disease. Researchers will also analyze tear proteins to see how they change with treatment. The trial involves 75 adults with dry eye and aims to understand both the device's effectiveness and the biological markers of the condition.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Rexon-Eye electrotherapy device
What this could lead to
If successful, this could point toward a better way to diagnose and manage dry eye disease using tear protein analysis.
What could go wrong
This is a small, early-stage study with only 75 participants, so results may not apply to everyone. The device's long-term benefits and safety are still being evaluated.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

75 people

The number who actually took part.

Started

Jan 2021

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * OSDI score ≥ 13, and * Fail one of the three diagnostic tests: * Non-invasive tear break-up time (NITBUT) less than 10s; * Tears osmolarity higher than or equals to 308 mOsm/L or inter-ocular difference \> 8 mOsm/L; * When assessing with slit lamp, shows more than 9 spots of conjunctival stain with lissamine green, more than 5 spots of corneal stain with fluorescein or lid wiper epitheliopathy (LWE) with lissamine green ≥ 2 mm in length and/or ≥ 25% sagittal width. Exclusion Criteria: * Any active ocular infections, inflammations or anomalies in eyelid; * Pregnant or lactating; * Uncontrolled, newly diagnosed systemic diseases or with modified long-term medications within 6 months; * Carrying active implantable devices (e.g., pacemakers and hearing aids)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dry eye are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

dry eye syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Dry eye Dry eye disease (DED)

Contacts and locations

Locations

  • The Hong Kong Polytechnic University, Hong Kong,

    Hong Kong, Hong Kong

More trials for these conditions

Other studies related to the condition(s) this trial covers.